NumberRecommendationSee section
Information and support4
8If there have been any concerns about early-onset neonatal infection before a baby is discharged, advise the parents and carers verbally and in writing that they should seek medical advice (for example, from NHS Direct, their general practice, or an accident and emergency department) if they are concerned that the baby:
  • is showing abnormal behaviour (for example, inconsolable crying or listlessness), or
  • is unusually floppy, or
  • has developed difficulties with feeding or with tolerating feeds, or
  • has an abnormal temperature unexplained by environmental factors (lower than 36°C or higher than 38°C), or
  • has rapid breathing, or
  • has a change in skin colour.
Risk factors for infection and clinical indicators of possible infection5.2
19Use the following framework based on risk factors and clinical indicators, including red flags (see tables 1 and 2), to direct antibiotic management decisions:
  • In babies with any red flags, or with two or more ‘non-red flag’ risk factors or clinical indicators (see tables 1 and 2), perform investigations (see recommendations 32–34) and start antibiotic treatment. Do not delay starting antibiotics pending the test results (see recommendations 40–42).
  • In babies without red flags and only one risk factor or one clinical indicator, using clinical judgement, consider:
    • whether it is safe to withhold antibiotics, and
    • whether it is necessary to monitor the baby’s vital signs and clinical condition – if monitoring is required continue it for at least 12 hours (at 0, 1 and 2 hours and then 2-hourly for 10 hours).
21If a baby needs antibiotic treatment it should be given as soon as possible and always within 1 hour of the decision to treat.5.2
Intrapartum antibiotics6
26Offer intrapartum antibiotic prophylaxis using intravenous benzylpenicillin to prevent early-onset neonatal infection for women who have had: 6
Investigations before starting antibiotics in the baby8
33Measure the C-reactive protein concentration at presentation when starting antibiotic treatment in babies with risk factors for infection or clinical indicators of possible infection.8
Antibiotics for suspected infection9
40Use intravenous benzylpenicillin with gentamicin as the first-choice antibiotic regimen for empirical treatment of suspected infection unless microbiological surveillance data reveal local bacterial resistance patterns indicating a different antibiotic.9
Investigations during antibiotic treatment10
48In babies given antibiotics because of risk factors for infection or clinical indicators of possible infection, measure the C-reactive protein concentration 18–24 hours after presentation.10
Decisions 36 hours after starting antibiotic treatment10
50In babies given antibiotics because of risk factors for infection or clinical indicators of possible infection, consider stopping the antibiotics at 36 hours if:
  • the blood culture is negative, and
  • the initial clinical suspicion of infection was not strong, and
  • the baby’s clinical condition is reassuring with no clinical indicators of possible infection, and
  • the levels and trends of C-reactive protein concentration are reassuring.
51Consider establishing hospital systems to provide blood culture results 36 hours after starting antibiotics to facilitate timely discontinuation of treatment and discharge from hospital.10
Care setting12
71When deciding on the appropriate care setting for a baby, take into account the baby’s clinical needs and the competencies necessary to ensure safe and effective care (for example, the insertion and care of intravenous cannulas).12

From: 1, Guideline summary

Cover of Antibiotics for Early-Onset Neonatal Infection
Antibiotics for Early-Onset Neonatal Infection: Antibiotics for the Prevention and Treatment of Early-Onset Neonatal Infection.
NICE Clinical Guidelines, No. 149.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2012 Aug.
Copyright © 2012, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.